Bevology relaunches Zenergize healthy drink tabs
SAN FRANCISCO Bevology recently relaunched its effervescent Zenergize Vitamin-InfuZed DrinkTabs, now with no sugar added.
“Consumers continue to seek more convenient ways to integrate nutritional food and beverage products into their on-the-go lifestyles without sacrificing product taste or value” stated Brad Barnhorn, chief executive officer of Bevology. “The DrinkTab category gives consumers a perfect solution that goes where they go and, unlike many of the so claimed healthy beverages, it makes a truly healthy beverage that delivers real, meaningful levels of nutrition without the sugar or calories.”
Zenergize DrinkTabs contain zero grams of sugar, two calories and are formulated with vitamins, minerals and herbal nutrients. The line is comprised of seven SKUs specially formulated to address specific need states, including Immunity, Hydrate, Energy+, Burn, Thrive, Empower and Chill.
The suggested retail price for a tube of 10 Vitamin-InfuZed DrinkTabs is $6.99.
The DrinkTabs are designed to be added to bottled water, and as such the ingredients are released at the time of consumption as compared to bottled and canned beverages-plus-vitamins that can travel through the supply chain for months before reaching the consumer.
FDA committee to review OTC decongestants
ROCKVILLE, Md. The Nonprescription Drugs Advisory Committee will consider the possibility of a revision to the final monograph for over-the-counter decongestants following a review of the safety and efficacy of phenylephrine in a Dec. 14 meeting, FDA said in a notice prepared for the Oct. 24 Federal Register, according to the Tan Sheet.
The meeting is one day after the FDA considers the potential switch of Merck’s Mevacor for the third time.
At the Dec. 14 meeting, the committee will discuss questions on the safety and effectiveness of PE hydrochloride and PE bitartrate in nonprescription decongestants raised in a Feb. 1 citizen petition.
The petitioners—University of Florida pharmacy professors Leslie Hendeles and Randy Hatton—assert that available data does not support the adult and pediatric dosing levels recognized as safe and effective in the monograph for OTC cough, cold, allergy, bronchodilator and antiasthmatic drug products. They requested FDA revise the monograph to increase the adult dose of PE hydrochloride from 10 mg to 25 mg and PE bitartrate from 15.6 mg to 40 mg.
Last week a pair of FDA advisory committees voted to discontinue the recommendation of children’s cough-and-cold remedies for children under the age of six.
NPA to hold Web conference on adverse-event reporting law
WASHINGTON The Natural Products Association on Monday announced the scheduling of a Web conference this Friday at 2 p.m. featuring two experts—Rick Kingston, president, regulatory and scientific affairs, SafetyCall International and Daniel Fabricant, vice president of scientific and regulatory affairs, Natural Products Association—to help companies understand both the broad and technical aspects of the new adverse-event reporting law.
“As the largest trade association representing both retailers and manufacturers, I can say there are a lot of questions and confusion about how these new rules will work,” Fabricant stated. “Every company needs to know and understand this new law and its ramifications, which is why we are conducting this special session. We will also use the knowledge gained from this session to inform our official comments that we submit to the FDA.”